### **Overview** RPG Life Sciences Ltd. is an **integrated, research-driven pharmaceutical company** with over 50 years of legacy, operating across **branded formulations, global generics, and synthetic Active Pharmaceutical Ingredients (APIs)** in both domestic and international markets. It is a part of the diversified **RPG Group**, a $5.2 billion conglomerate with interests in infrastructure, tyres, pharma, and technology. The company operates across **three core business segments**: 1. **Domestic Formulations** (India & Nepal) 2. **International Formulations** (oral solid dosage generics and branded generics) 3. **Synthetic APIs** With a presence in **over 50 countries**, three manufacturing facilities, and a workforce of over **1,300 employees**, RPG Life Sciences is transitioning from a domestic-focused player to a **globally integrated, innovation-led enterprise**. --- ### **Strategic Business Segments & Growth Engines** #### **1. Domestic Formulations (Primary Growth Engine)** - **Revenue Contribution**: Over 65% of total revenue (as of recent years). - **Therapeutic Focus**: Mass, Mass-specialty, and Specialty segments; acute and chronic therapy areas. - **Key Brands**: "Textbook" brands with strong equity — *Azoran (Immunosuppressant), Aldactone, Naprosyn, Norpace, Lomotil, Serenace.* - **Specialist Reach**: Strong penetration among nephrologists, rheumatologists, cardiologists, diabetologists, urologists, and oncologists. - **Growth Strategy (Five-Pillar Approach)**: 1. **Portfolio rejuvenation** through new launches in **biosimilars, chronic, and specialty therapies** (e.g., oncology, CVM, urology, rheumatology). 2. **Life Cycle Management (LCM)** of legacy brands (e.g., *Naprosyn+*, *Aldactone-F*). 3. **Expanded field force and digital engagement** (e.g., *RPGserv*, e-CMEs) to deepen customer coverage. 4. **Salesforce productivity enhancement** via training, digital tools (e.g., *Rxcer 2.0*), and scientific selling. 5. **Profitability optimization** through manufacturing efficiency, cost control, and focus on high-margin products. - **MABs (Monoclonal Antibodies) Portfolio**: Robust performance driven by multi-branding and targeted medico-marketing. - **Recent Performance**: Grew at **13.5% YoY in H1 FY26**, significantly outpacing the overall Indian pharma market (7.4% growth). #### **2. International Formulations (Second Growth Engine)** - **Revenue**: ₹132.3 crore in FY25, up **24.4% YoY**. - **Markets**: Regulated (UK, Canada, Germany, Australia, France) & emerging (Myanmar, Vietnam, Philippines, South Africa, Egypt, Colombia). - **Key Products**: - **Generics**: Azathioprine, Sodium Valproate PR, Nicorandil, Sertraline. - **Branded Generics**: *Azoran, Mofetyl, Arpimune* (Nephrology), *Siloxogene, Tricaine MPS* (GI), *Dipsope, Diasafe, Losatec* (CVM). - **Strategic Pillars**: 1. **Expand immunosuppressant portfolio** (Azathioprine, Mycophenolate, Tacrolimus, Cyclosporine). 2. **Focus on complex generics and niche molecules** with specialized manufacturing needs (low competition). 3. **Expand into emerging markets** — including Myanmar, Vietnam, Philippines, Egypt, Sudan, Thailand, Sri Lanka. - **Recent Milestones**: - Won **CENABAST tender in Chile**. - Secured **product approvals in UAE and Mexico**. - Filed **ANDS application with Health Canada**; submitted registration in **Croatia**. - Signed **outlicense deal with Saudi pharma firm** for a complex generic. - First **pan-European outlicense and supply deal** for an immunosuppressant. - **Manufacturing Advantage**: - **Ankleshwar Plant F2**: EU GMP, TGA Australia, Health Canada approvals — supports regulated market access. - **Plant F1**: WHO GMP, Nigerian & Kenyan regulatory approvals — serves emerging markets. #### **3. Active Pharmaceutical Ingredients (APIs) (Third Growth Engine)** - **Focus**: High-value, low-volume, niche APIs from **mature, stable molecules**. - **Therapeutic Areas**: Immunosuppressants, antihypertensives, aquaretics, antiepileptics, antifungals, antidepressants. - **Key APIs**: Azathioprine, Quinfamide, Haloperidol, Risperidone, Pantoprazole. - **Strategic Importance**: - Enables **backward integration** for International Formulations. - Enhances **supply chain resilience** and reduces import dependence (aligned with Indian government policy). - **Global Footprint**: Major markets include LATAM, Germany, China, South Korea, Iran, Bangladesh, Egypt, India. - **Growth Strategy**: - Expand into new geographies and customers. - Support **"Manthan" initiative** to transform API into a **formidable business segment**. - Develop **limited-competition molecules** with complex manufacturing. - **Manufacturing & Certifications**: - **Navi Mumbai API Plant**: WHO GMP, TGA Australia, PMDA Japan approved — ensures global compliance. - Ongoing **modernization and capacity expansion** to support scale-up. --- ### **Strategic Growth Framework (2025–2026)** RPG Life Sciences is executing a **seven-pillar transformation strategy** to drive sustainable, profitable growth: | **Strategic Pillar** | **Key Initiatives** | |----------------------|---------------------| | **1. Brand & Portfolio Building** | Scale **Naprosyn** into a ₹100+ crore OTC "Mega Brand"; grow **Immunosuppressants** into a ₹200+ crore Rx portfolio. | | **2. API Business Expansion** | Drive "Manthan" initiative; focus on **niche, low-competition APIs**; deepen backward integration. | | **3. Global Footprint Expansion** | Enter new regulated and emerging markets (e.g., Southeast Asia, Middle East, Africa, Latin America). | | **4. Digital Transformation** | Deploy **RPGserv** (phygital platform for 80,000+ doctors), **e-CMEs**, **Rxcer 2.0** for salesforce analytics. | | **5. M&A & Partnerships** | Formal **M&A framework in place**; targeting margin-accretive brands and therapy expansions; evaluating synergistic deals. | | **6. Modern Manufacturing** | Invested **₹140 crore (since FY22)** in plant modernization; 2x capacity expansion underway; facilities compliant with **EU, PICS, TGA** standards. | | **7. Sustainability & ESG** | Embed **ESG principles** into operations; focus on green manufacturing, waste reduction, solvent recovery, and long-term sustainability. | --- ### **Innovation & R&D** - **Dedicated R&D Units**: For APIs and formulations. - **Focus Areas**: - **APIs**: Niche molecules, process innovation, stability studies. - **Formulations**: Immunosuppressants, biosimilars, complex generics, chronic and specialty therapies (NSAIDs, antidepressants, antidiabetics). - **New Product Pipeline**: Includes products for **EU and emerging market registrations**. - **Augmented Labs**: GLP-compliant labs and new R&D infrastructure to accelerate development. --- ### **Financial & Operational Highlights** - **Revenue Growth**: International Formulations segment growing at **double-digit CAGR**: ₹92.16 crore (FY23) → ₹106.31 crore (FY24) → ₹132.30 crore (FY25). - **Cost Optimization**: Sustained **5-year run of year-on-year margin expansion** via re-engineering legacy products and structural cost control. - **Capital Expenditure**: Over **₹100 crore invested** in modernizing plants at Navi Mumbai (API) and Ankleshwar (Formulations). - **Cash Flow**: Surplus from **sale of surplus land** in Navi Mumbai to be reinvested in growth. --- ### **Key Differentiators** - **Integrated Model**: Full vertical integration from API to formulation. - **Regulatory Compliance**: Facilities approved by **EU GMP, WHO GMP, TGA, Health Canada, PMDA Japan** — enabling export readiness. - **Niche Leadership**: **Immunosuppressants** — domestic market leader; global recognition in Azathioprine. - **Digital Edge**: Pioneering **phygital engagement** platforms (RPGserv) to enhance doctor connectivity. - **ESG Focus**: Committed to **sustainable operations**, green chemistry, and waste reduction.